AASLD 2026:UDCA 生化应答与 PBC 长期预后相关
从PBC长期预后到AIH辅助治疗|AASLD国际研究新发现
AASLD 2026 大会报告了两项研究:一项显示 UDCA 生化应答可预测 PBC 患者 5 年肝失代偿和死亡风险,另一项发现不足应答患者二线治疗应用不足。研究强调了 UDCA 应答在 PBC 和 AIH 治疗中的重要性。
2026年11月5日-9日,全球肝病领域顶级学术盛会-The Liver Meeting 2026 (AASLD 2026)在美国•丹佛召开。本届大会汇聚来自世界各地的肝病临床专家与基础研究学者,围绕病毒性肝炎、代谢功能障碍相关脂肪性肝病、肝硬化及其并发症、肝癌、肝移植和肝病基础研究等领域,集中展示前沿研究成果与临床诊疗新进展。
为助力广大读者精准捕捉会议的学术精髓,及时洞悉领域前沿动态,肝胆相照平台特别甄选会议摘要中的热点研究内容,本篇专题报道将聚焦“自身免疫性肝病”这一关键领域,为广大同仁提供最新研究进展,展望其在临床实践中的广阔应用前景。
一 摘要编号:0009
UDCA治疗12个月的生化应答可预测PBC患者5年肝失代偿和死亡
TWELVE-MONTH BIOCHEMICAL RESPONSE TO UDCA PREDICTS FIVE-YEAR DECOMPENSATION AND MORTALITY IN PRIMARY BILIARY CHOLANGITIS: A PROPENSITY-MATCHED LANDMARK COHORT STUDY
作者:EzzElDien A. Ibrahim1 Mahmoud Majed Mansour1 Mostafa Adel T. Mahmoud2 Nourhan Saleh1 Darian Fard1 Mohammad Alabbas3 Saranya Arumugam4 Ahmad Alhusen5 Khulood T Ahmed1
1 University of Missouri, Columbia, MO, USA
2 Beni Suef university, Beni Suef, Egypt
3 Cleveland Clinic Foundation
4 University of California, Riverside school of medicine
5 Advocate Illinois Masonic Medical Center
背景
原发性胆汁性胆管炎(PBC)属于免疫介导的慢性胆汁淤积性肝病,熊去氧胆酸(UDCA)为一线首选药物。12 个月生化应答标准(如 Paris Ⅱ 标准)已在 UK‑PBC、GLOBE 登记队列中用于指导是否升级治疗,但该标准在真实世界多中心电子病历人群中对 5 年硬性临床终点的预测价值尚缺乏验证。
Background:Primary biliary cholangitis (PBC) is a chronic immune-mediated cholestatic liver disease for which ursodeoxycholic acid (UDCA) is first-line therapy. Biochemical response at 12 months, assessed by criteria such as Paris II, anchors treatment-escalation decisions in registry cohorts (UK-PBC, GLOBE), but real-world multi-center EHR validation against hard 5year clinical endpoints remains limited.
方法
本研究基于 TriNetX Research USA 数据库(覆盖 112 家医疗机构、约 1.47 亿成人)构建回顾性倾向评分匹配的 12 个月里程碑队列。纳入 2013—2024 年启动 UDCA 治疗、年龄≥18 岁的 PBC 患者,要求至少 2 次间隔≥30 天的 ICD‑10 K74.3 诊断记录。采用诊断后 9~15 个月的碱性磷酸酶(ALP)与总胆红素判定 12 个月应答状态:改良 Paris Ⅱ 应答定义为 ALP≤130 U/L 且总胆红素≤1.0 mg/dL,任意一项不满足即为无应答;受电子病历数据限制,未纳入 AST 指标,直接采用绝对值阈值,而非相对于正常值上限的倍数。
排除既往存在肝细胞癌、肝移植、HIV、HBV 感染以及已经使用 PBC 二线药物的患者。基于人口学特征、肝病相关情况、行为相关合并症、基线实验室指标和就诊类型等 29 项变量开展 1∶1 倾向评分匹配,匹配后分类变量标准化均数差均<0.05。分析里程碑时间点之后第 1~1825 天新发肝失代偿复合终点、肝移植、肝细胞癌、全因死亡以及二线治疗启动;在对应终点观察窗口前已发生目标事件的病例予以剔除,采用 Cox 回归计算风险比,规避不死时间偏倚。
Methods: Retrospective propensity-matched landmark cohort using TriNetX Research USA (147M adults, 112 healthcare organizations). Adults ≥18 with PBC ( ≥2 ICD-10 K74.3 codes ≥30 days apart, 2013–2024) initiating UDCA were classified at a 12-month landmark using ALP and total bilirubin measured 9–15 months after the index diagnosis: responders met modified Paris II criteria (ALP ≤130 U/L and bilirubin ≤1.0 mg/ dL); nonresponders failed one or both. AST was not included due to EHR data limitations; absolute thresholds were used as a proxy for ULN-based cutoffs. Preindex HCC, liver transplant, HIV, HBV, and prior second-line PBC therapy were excluded. 1:1 propensity matching on 29 covariates (demographics, liver and behavioral comorbidities, baseline labs, encounter types) achieved all categorical SMDs < 0.05. Outcomes ascertained days 1–1825 post-landmark: composite hepatic decompensation, liver transplant, HCC, all-cause mortality, and second-line PBC therapy initiation; patients with the outcome before the window were excluded for that outcome only (incident-event analysis). Cox proportional hazards models estimated hazard ratios (HR) from the landmark date forward, eliminating immortal-time bias.
结果
最终纳入 2911 对匹配患者,平均年龄 61 岁,女性占 87%,白人占 77%。相较于无应答患者,生化应答者 5 年肝失代偿复合终点风险更低(HR=0.60,95% CI:0.51~0.70;5 年无事件生存率 75.9% 对比 67.7%,P<0.001),全因死亡风险同样更低(HR=0.74,95% CI:0.65~0.84,P<0.001)。肝移植(HR=0.82,95% CI:0.66~1.01,P=0.06)与肝细胞癌(HR=0.85,95% CI:0.63~1.14,P=0.28)呈现获益趋势,但未达到统计学显著性。应答组启动 PBC 二线治疗的比例显著更低(HR=0.21,95% CI:0.17~0.27)。原文摘要同时提及应答组 5 年肝失代偿绝对发生率下降 6.6 个百分点,但该句在原始 PDF 中表述不完整。
Results:2,911 matched pairs (mean age 61, 87% female, 77% White) were analyzed. Over 5 years, biochemical responders had lower composite hepatic decompensation (HR 0.60, 95% CI 0.51–0.70; 5-year event-free survival 75.9% vs 67.7%; p < 0.001) and lower all-cause mortality (HR 0.74, 95% CI 0.65–0.84; p < 0.001). Liver transplant (HR 0.82, 95% CI 0.66–1.01; p = 0.06) and hepatocellular carcinoma (HR 0.85, 95% CI 0.63–1.14; p = 0.28) trended favorably without reaching statistical significance, likely reflecting limited 5-year event accrual. Second-line PBC therapy initiation was substantially lower among responders (HR 0.21, 95% CI 0.17–0.27), consistent with clinical practice escalating therapy in nonresponders. Absolute 5-year differences in the responder arm: 6.6 percentage-point lower decompensation incid.
结论
这项大样本真实世界队列研究显示,UDCA 治疗 12 个月达到改良 Paris Ⅱ 标准与后续 5 年更低的肝失代偿及死亡风险相关,支持该标准作为预后判断和升级治疗决策的重要依据。
Conclusion:In a large realworld EHR cohort, modified Paris II response at 12 months was associated with lower 5-year hepatic decompensation and mortality, supporting its use as a prognostic anchor for treatment escalation.
二 摘要编号:1152
UDCA生化应答不足的PBC患者二线治疗应用不足:美国真实世界队列
FEWER THAN ONE IN FOUR PBC PATIENTS WITH INADEQUATE UDCA RESPONSE RECEIVE SECOND-LINE THERAPY: A DECADE-LONG NATIONWIDE ANALYSIS OF 3,799 PATIENT
作者:Jarell Jie-Rae Tan1 Aldo Montano-Loza2 Yu Jun Wong3
1 Department of Gastroenterology & Hepatology, Changi General Hospital
2 Liver Unit, Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada
3 Department of Gastroenterology & Hepatology, Changi General Hospital Singapore
背景
目前已有多种二线药物获批用于熊去氧胆酸(UDCA)应答不佳的原发性胆汁性胆管炎(PBC)患者,但临床中二线方案的实际应用现状尚不明确。本研究依托美国大型队列,结合二线药物的获批时间进程,分析二线药物的处方模式、时间趋势以及启动二线治疗的临床影响因素。
Background:Multiple second-line agents are now approved for primary biliary cholangitis (PBC) patients who fail ursodeoxycholic acid (UDCA), yet the realworld utilization of second-line (2L) treatment remains unknown. We examined real-world prescribing patterns, temporal trends, and clinical determinants of second-line therapy initiation across a large US-based cohort spanning the complete regulatory history of 2L PBC therapies.
方法
本回顾性队列分析基于 TriNetX 全球研究网络 2015—2025 年 170 家医疗机构(以美国机构为主)的去标识化电子病历数据。纳入 UDCA 持续治疗至少 12 个月、碱性磷酸酶(ALP)持续升高的成年 PBC 患者;合并其他慢性肝病、失代偿期肝硬化、既往肝移植、恶性肿瘤、终末期肾病及痴呆的患者予以排除。采用多变量 logistic 回归筛选二线治疗启动的预测因素,并按照不同药物的监管获批阶段评估处方格局变化。
Methods:We performed a retrospective cohort study using the TriNetX global research network with deidentified electronic health records from 170 predominantly US healthcare organizations, 2015–2025. Eligible patients were adults with PBC and persistent alkaline phosphatase elevation after ≥12 months of UDCA, without concomitant chronic liver disease, decompensated cirrhosis, previous liver transplantation, malignancy, end stage kidney disease or dementia. Predictors of second-line initiation were identified by multivariable logistic regression. Prescribing trends were analyzed across sequential regulatory periods.
结果
3799 例 UDCA 生化应答不充分患者(定义为 ALP>3 倍正常值上限)中,847 例(22.3%)接受过任意一种二线治疗,提示近 3000 例符合升级治疗指征的患者在 10 年随访期间未接受二线药物。队列女性占 85.8%,平均年龄 66 岁,31% 合并肝硬化。二线药物以奥贝胆酸最为常用(10.9%),其次为贝特类(9.5%)、seladelpar(4.4%)及 elafibranor(3.2%)。年轻、女性、于学术中心就诊是启动二线治疗的独立预测因素;摘要同时提到男性及 35 岁以下人群二线治疗启动率更低(均 P<0.01),原文摘要中年龄相关表述存在方向不一致。2025 年相关新药获批后,二线治疗启动率由 19.3% 小幅上升至 23.1%(P<0.001),处方重心由奥贝胆酸向 PPAR 激动剂转移,但总体治疗覆盖率仍显著低于符合指南指征的人群规模。
Results: Of 3,799 patients with documented incomplete biochemical response to UDCA (defined as ALP>3x ULN), only 847 (22.3%) received any secondline therapy, which translates to close to 3,000 eligible patients being untreated over a decade. The cohort was 85.8% female, with a mean age of 66 years; 31% already had cirrhosis. Obeticholic acid was most commonly prescribed (10.9%), followed by fibrates (9.5%), seladelpar (4.4%), and elafibranor (3.2%). Younger age, female sex, and care at academic centers independently predicted 2L treatment uptake. Notably, 2L initiation rates were lower amongst higher risk group including male patients (vs female), and those under 35 years of age (vs > = 35 years) (both p < 0.01). Following regulatory approvals in 2025, 2L initiation rates increased modestly (23.1% vs. 19.3%; p < 0.001), accompanied by a marked shift from obeticholic acid toward PPAR agonists, though overall utilization remained far below what guideline-eligible disease burden would demand.
结论
在10年观察期内,约3000例存在明确UDCA治疗失败证据的PBC患者(含肝硬化人群)未接受二线升级治疗。新药上市带来了处方结构的一定改变,但治疗覆盖率提升幅度有限,亟需优化 UDCA 应答不足患者的升级治疗管理。
Conclusion:Across 102 US healthcare systems over ten years, close to 3,000 PBC patients with documented UDCA failures, including those with established cirrhosis, never received a second-line agent. Temporal trends reflect increased awareness with new drug approvals, but only marginally increase the treatment coverage. Further work is needed to address this gap for UDCA-refractory PBC patients.
三 摘要编号:1315
6-巯基嘌呤与硫唑嘌呤辅助自身免疫性肝炎激素诱导治疗的比较
6-MERCAPTOPURINE VS. AZATHIOPRINE AS ADJUNCTIVE THERAPY DURING HIGH-DOSE CORTICOSTEROID INDUCTION IN AUTOIMMUNE HEPATITIS: A PROPENSITY SCORE–MATCHED COHORT ANALYSIS
作者:Bianca Patel1 Jashanveer Johal1 Archana Salek1 Mahmoud Al-Bataineh1 Brandon Cunha1 Abdallah Hussein1 Jason Hyman1 Yecheskel Schneider1
1 Virtua Health
背景
硫唑嘌呤(AZA)是指南推荐用于自身免疫性肝炎(AIH)的激素节约辅助药物;6‑巯基嘌呤(6‑MP)作为其活性代谢产物,多用于 AZA 不耐受的患者。目前尚缺少匹配的真实世界队列,对比二者在大剂量糖皮质激素诱导阶段的疾病控制效果与安全性是否相当。
Background:Azathioprine (AZA) is the guideline standard steroid-sparing adjunct in autoimmune hepatitis (AIH), but 6-mercaptopurine (6-MP), its active metabolite, is used as an alternative in patients with AZA intolerance. Whether 6-MP provides equivalent disease control and safety during the high-dose induction phase of corticosteroid therapy has not been characterized in a real-world matched cohort.
方法
基于 TriNetX 全球协作网络筛选 AIH 患者,纳入标准为使用泼尼松 10~50 mg,并在 1 个月内联合启动 6‑MP 或 AZA 治疗。排除基线合并肝硬化、原发性硬化性胆管炎、肝移植术后或肾上腺功能不全的患者;经 1∶1 倾向评分匹配后,两组各 166 例。研究终点包括静脉激素使用、生化缓解、泼尼松减量至≤7.5 mg、血细胞减少、住院、死亡及新发肝硬化。
Methods:Using the TriNetX Global Collaborative Network, we identified AIH patients receiving prednisone (10–50 mg) with either 6-MP or AZA initiated within 1 month. Patients with cirrhosis, primary sclerosing cholangitis, liver transplant, or adrenal insufficiency were excluded. After 1:1 propensity score matching, 166 patients remained in each cohort. Outcomes included IV steroid use, biochemical remission, transition to low-dose prednisone ( ≤7.5 mg), cytopenia, inpatient encounters, mortality, and incident cirrhosis.
结果
所有研究结局的组间差异均未达到统计学显著性。静脉激素使用率相近(33.1% 对比 30.7%,HR=1.00,P=0.99)。AZA 组生化缓解率数值更高(86.1% 对比 78.9%,HR=0.82,P=0.098),AST/ALT 恢复正常所需时间更短(66 天对比 105 天)。AZA 组泼尼松减至低剂量的比例更高(53.0% 对比 47.6%,HR=0.83,P=0.24),且减量耗时更短(668 天对比 1311 天)。6‑MP 组血细胞减少事件更多见(59.0% 对比 48.8%,HR=1.33,P=0.055),且发生时间更早(583 天对比 1988 天)。住院、死亡及新发肝硬化的发生率两组相当。以上风险比的参照方向与原文摘要保持一致。
Results:No outcome differed significantly between groups. IV steroid use was similar (33.1% vs 30.7%; HR 1.00, p = 0.99). AZA showed numerically higher biochemical remission (86.1% vs 78.9%; HR 0.82, p = 0.098) and faster AST/ALT normalization (66 vs 105 days). Transition to low-dose prednisone was more frequent with AZA (53.0% vs 47.6%; HR 0.83, p = 0.24), with shorter time to taper (668 vs 1,311 days). Cytopenia occurred more often with 6-MP (59.0% vs 48.8%; HR 1.33, p = 0.055) and developed earlier (583 vs 1,988 days). Inpatient encounters, mortality, and cirrhosis rates were comparable.
结论
6‑MP 与 AZA 用于 AIH 诱导治疗阶段的整体临床结局相近。AZA 在生化缓解、激素减量速度方面呈现获益趋势,而 6‑MP 与更早、更高的血细胞减少风险相关。6‑MP 可作为部分患者的替代选择,但需加强血液学指标监测。
Conclusion:6-MP and AZA demonstrated similar clinical outcomes during AIH induction therapy. AZA showed trends toward faster biochemical remission and steroid taper, whereas 6-MP was associated with earlier and more frequent cytopenia. These findings support 6-MP as an alternative for selected patients while underscoring the need for hematologic monitoring.
版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
来源:梅斯医学·临床资讯 · news.medsci.cn